PTJ
JBIO

Paul Tudor Jones’s Jade Biosciences JBIO Stock Holding History

Paul Tudor Jones’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,200
Closed -$373K – 3597
2025
Q4 		$373K Buy
+24,200
New +$284K ﹤0.01% 2900

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Paul Tudor Jones's JBIO Position: Q1 2026 in Review

Paul Tudor Jones sold out of Jade Biosciences (JBIO) in Q1 2026, closing a stake of 24,200 shares — an estimated $373K sold.

Paul Tudor Jones first reported a position in JBIO in Q4 2025 and held it in 1 quarter. The position peaked at $373K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Paul Tudor Jones reported no remaining Jade Biosciences position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 24,200 Jade Biosciences shares in Q1 2026, an estimated $373K.
  • Paul Tudor Jones first reported a position in Jade Biosciences in Q4 2025 and held it in 1 quarter.
  • Paul Tudor Jones's Jade Biosciences position peaked at $373K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.